Get Meyka ProOur News
HOT
Developer Portal
Log inSign up
Meyka LogoMeyka
BETA
Meyka AI is in beta – Features are evolving, and your feedback helps us improve!
Meyka Analyst
BusinessExecutive TradesInsights & GuidesInvestingEducationMarketMarket NewsTechnical IndicatorsTechnology
Overview
Forecasting
Trending
AI Analysis
Trending
Alt-Data
New
Fundamentals
Technical Analysis
Peers
News
Overview
Forecasting
Trending
AI Analysis
Trending
Alt-Data
New
Fundamentals
Technical Analysis
Peers
News
Loading...

argenx SE

ARGX•NASDAQ
Healthcare
Biotechnology
$780.25
$-7.70(-0.98%)
U.S. Market opens in 45h 44m

ARGX News Today: Stay Updated with the Latest argenx SE News in Real Time

Find ARGX news now at Meyka AI. Stay informed with the latest argenx SE stocks updates, including price news, market analysis, and expert insights.

Cowen Maintains Buy on argenx SE (ARGX) March 13, 2026
📅 1 month ago

Cowen Maintains Buy on argenx SE (ARGX) March 13, 2026

Cowen maintains Buy on argenx SE; our ARGX analyst rating review covers implications, price move, and Meyka Grade A

Read more
Maintained Buy by BofA on ARGX argenx SE Feb 2026
📅 2 months ago

Maintained Buy by BofA on ARGX argenx SE Feb 2026

BofA maintained Buy and raised ARGX price target to $1,013 — ARGX analyst rating update and implications

Read more
Argenx Releases H1 2025 Financials and Q2 Business Highlights
📅 9 months ago

Argenx Releases H1 2025 Financials and Q2 Business Highlights

Argenx, a global immunology company dedicated to improving the lives of people suffering from severe autoimmune diseases, has published its first-half 2025 financial results and second-quarter business highlights. The company’s robust pipeline development and strategic partnerships continue to shape its position as a biotech leader in rare diseases. Strong Revenue Growth Driven by Vyvgart Franchise…

Read more

ARGX News FAQ

Meyka LogoMeyka

Meyka is the best AI Powered Real-Time Stock and Crypto News Platform that helps investors make decisions based on Historical Data.

Connect With Us

Legal

  • Privacy Policy
  • Terms of Service
  • Disclaimer
  • Cookie Policy

Stock Market GPTs

  • Stock Research GPT
  • Stock Earnings GPT
  • Stock Screener GPT

Resources

  • Get Meyka Pro
  • Contribute
  • Contribute on Medium
  • Blog
  • Education
  • About Us
  • Contact Us
  • Upcoming Features
  • Developer Portal
  • Subscribe to Our Newsletter

Market

  • Market Overview
  • Screener
  • Senate Trades
  • Senate Disclosures
  • Earnings Calendar
  • Economic Calendar
  • Dividends Calendar
  • News
  • Press Release

Screener Ideas

  • Top Gainers
  • Top Losers
  • AI Stocks
  • Most Active
  • Unusual Volume
  • New High
  • New Low
  • REIT Stocks
  • Technology Stocks
  • Finance Stocks
  • Dividend Stocks
  • Growth Stocks
  • High ROE Stocks

Legal Disclaimer

The information provided by Meyka AI PTY LTD is for informational and research purposes only and does not constitute financial, investment, or trading advice. Meyka is a research platform, not a financial advisory service. Investing in financial markets involves risks, and past performance does not guarantee future results. Users should conduct their own due diligence, consult with professional financial advisors, and assess their risk tolerance before making investment decisions. Meyka and its operators are not liable for any financial losses incurred from the use of information on this platform. The data provided is derived from publicly available sources and is believed to be reliable but may not always be accurate or up to date. Users should independently verify information and not rely solely on Meyka for financial decisions. By using Meyka, you acknowledge that it does not provide financial advice or recommendations and agree to seek guidance from a qualified financial professional before making any investment decisions.

Ads powered by Playwire

Advertise on this site.

© 2026 Meyka AI PTY LTD. All rights reserved.

Quick view of what's moving in the market today.